Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

Leukemia Research
Apostolia-Maria TsimberidouGuillermo Garcia-Manero

Abstract

Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.

References

Apr 22, 1993·International Journal of Cancer. Journal International Du Cancer·I SaikiI Azuma

❮ Previous
Next ❯

Citations

Apr 3, 2009·International Journal of Hematology·Arturo Vega-RuizFarhad Ravandi
Feb 28, 2008·Current Opinion in Hematology·Sergio Amadori, Roberto Stasi
Mar 27, 2010·Advances in Hematology·Leonardo PacilliIgnazio Majolino
Nov 8, 2008·Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine·Da-zhuo ShiKe-ji Chen
Mar 21, 2008·Expert Opinion on Biological Therapy·Roberto Stasi
Dec 15, 2010·Expert Opinion on Biological Therapy·Massimo Breccia, Francesco Lo-Coco
Oct 19, 2007·Cancer Treatment Reviews·Roberto StasiSergio Amadori
Jan 18, 2006·British Journal of Haematology·Apostolia-Maria TsimberidouHagop M Kantarjian
Jun 11, 2005·World Journal of Gastroenterology : WJG·Qin-Shu ShaoJin-Jing Ke
May 8, 2018·Journal of Pediatric Hematology/oncology·Michael J McNeilKatherine Tarlock
Apr 13, 2012·Acta Radiologica·Alexey SurovJasmin Abbas
Jun 23, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P RaananiI Ben-Bassat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.